Clinical, epidemiologic and therapeutic considerations on Chronic Chagas Cardiomyopathy
Abstract
Introduction: The Chagas Disease is a zoonosis caused by the protozoa Trypanosoma cruzi, three phases are clinically recognized: acute, indeterminate and chronic, the Chronic Chagas Cardiomyopathy is the main manifestation of the chronic phase. Objective: To know the main clinical, epidemiologic characteristics and the therapeutics of the admitted patients with Chronic Chagas Cardiomyopathy diagnosis in the Integral Diagnostic Center of Bejuma, Carabobo State, Bolivarian Republic of Venezuela. Method: An observational descriptive, cross sectional study was carried out from September 1rst, 2007 to August 31, 2009, the work universe was constituted by 395 patients older than 18 years admited in the period mentioned before, the sample was constituted by 43 patients. Results: the masculine sex was the most affected and the age group of 76 years and more was the one that prevailed in both sexes; 72.0% of patients do not remember to have got sting for the vinchuca; the peripheral edemas and exertional dyspnea were the main clinical manifestation; the more frequent electrocardiography alteration was the right Bundle-Branch Block; the inhibiting of angiotensin-converting enzyme and the loop diuretics were the most used medicines. Conclusions: Chronic Chagas Cardiomyopathy constituted 10.8% of all admited cases, most of the patients infected with Trypanosoma cruzi did not know that they were suffering this disease and those who knew it do not know the risk of sudden death for arrhythmias.Downloads
References
Kirchhoff LV. Tripanosomosis. En: Fauci AS, Kasper LD, Braunwald E, Hauser Sl, Logo DL, Jameson LJ, et al. Harrison. Principios de Medicina Interna. 17 ed. México: Mc Graw Hill; 2008. p.1300-05.
Garrido F, cordova J, Rivas L, Montiel L, Luces G, Celys L, et al. Guía para el Diagnóstico, Manejo y Tratamiento de Enfermedad de Chagas en fase aguda a nivel de los Establecimientos de Salud. 1 ed. República Bolivariana de Venezuela: s.d.; 2007.
Gascón J, Albajar P, Cañas E, Flores M, Prat JG, Herrera RN, et al. Diagnóstico, manejo y tratamiento de la cardiopatía chagásica crónica en áreas donde la infección por Trypanosoma cruzi no es endémica. Rev Española Cardiol. 2007; 60: 285-93.
Días JCP. Natural history of Chagas´ disease. Arq Bras Cardiol. 2008; 65:359-66.
Basquiera AL, Capra R, Omelianiuk M, Amuchástegui M, Madoery RJ, Salomone OA. Concentraciones séricas de troponina T en pacientes con enfermedad de Chagas crónica. Rev Esp Cardiol. 2008; 56(7): 742-4.
Umelisa Chagas [Internet]. La Habana: Centro de Inmunoensayo; 2007 [actualizada 8 Ene 2014; citado 8 Ene 2014]. Disponible en:
http://www.tecnosuma.com/Informacion/htm/UM2014.htm
Carlier Y, Luquetti AO, Días JCP, Truyens C. Chagas Disease (American Trypanosomiasis) [Internet]. Emedicine.com; 2004 [citada 10 Oct 2009] [aprox. 4 pantallas]. Disponible en: http://www.emedicine.com/med/topic327.htm
Carrasco GH, Gómez C, Parada H, Guerrero L, Durán D, Molina C, Faieta A. Determinantes pronósticos en la miocardiopatía chagásica crónica. Rev Facult Med. 1992; 1(4):152-62.
Zulantay I, Bozán F, Salas C, Zilleruelo N, Osuna A, Gil LC, et al. Enfermedad de Chagas crónica. Ausencia de Triatoma infestans intradomiciliario y persistencia de Trypanosoma cruzi circulante post-terapia. Parasitol Latinoam. 2008; 59:93-98.
Alonso VC. Vinchucas, Trypanosomas y demás familia: nociones sobre la enfermedad de Chagas. Acta Nova. 2008; 2(3):423-31.
Vidaurre T, Córdova G, Pérez L, Córdova E, Saldías J, Vivar A. Enfermedad de Chagas en sujetos asintomáticos con y sin alteraciones electrocardiográlficas en una zona endémica. Bol Soc Peruana Med Int. 1999; 12(3):125-36.
Auger O, Caravello JL, Barisani G, Bustamante-Labarta H, Castagnino
J, Grill I, et al. Miocardiopatía chagásica dilatada. Rev Arg Cardiol. 2007; 70(1):70-87.
Storino R, Milei J. Enfermedad de Chagas. Buenos Aires: Mosby-Doyma; 1994.
Roca GR, Smith V, Paz E, Lasada J, Serret B. Temas de Medicina Interna. 4 ed. La Habana: Ecimed; 2002.
Keller L. El paciente con miocardiopatía chagásica crónica (I):
sospecha y estudio básico. rol del electrocardiograma.Curso Intensivo sobre Enfermedad de Chagas; 2005 [Internet]. 2009 [citada 15 May 2009] [aprox. 6 pantallas]. Disponible en: http://www.fac.org.ar/ccvc/llave/c325/keller.php/
Tonero O. El Paciente con Miocardiopatia Chagásica Crónica (II). Curso Intensivo sobre Enfermedad de Chagas; 2005 [Internet]. 2009 [citada 15 May 2009] [aprox. 6 pantallas]. Disponible en: http://www. www.fac.org.ar/ccvc/llave/c326/c326/
Puigbó J. Contribución al estudio de la miocardiopatía chagásica crónica en Venezuela. Una visión panorámica. Parte II. Gac Med Caracas. 2001; 109(3):304-17.
The Rales investigators: effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the randomized aldactone evaluation study [RALES]. Am J Cardiol. 1996; 78:902-07.
The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with herat failure. N Engl J Med. 1997; 336(8):525-33.
Packer M, O Conner C, Ghali JK. Effect of Amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med. 1996; 335:1107-14.
Herrera RN, Díaz E, Pérez R, Chaín S, Sant-Yacumo R, Rodríguez E, et al. Estado protrombótico en estadios tempranos de la enfermedad de Chagas crónica. Rev Esp Cardiol. 2003; 56:377-82.
Downloads
Published
How to Cite
Issue
Section
License
Those authors who have publications with this journal accept the following terms of the License CC Attribution-NonCommercial 4.0 International (CC BY-NC 4.0):
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- NonCommercial — You may not use the material for commercial purposes .
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
